About Curium pharma
Curium Pharma is a leading nuclear medicine company that has been providing exceptional outcomes to patients for many years. The company is dedicated to enabling the highest quality care by developing and manufacturing innovative diagnostic and therapeutic radiopharmaceuticals. Curium Pharma's products are used in hospitals, clinics, and research institutions around the world.
The company was founded in 2017 when IBA Molecular and Mallinckrodt Nuclear Medicine LLC merged their businesses. Since then, Curium Pharma has become a global leader in nuclear medicine with over 50 years of experience in the industry. The company operates from more than 6 locations worldwide with over 1,500 employees.
Curium Pharma's mission is to improve patient outcomes by providing high-quality radiopharmaceuticals that enable accurate diagnosis and effective treatment of diseases such as cancer, heart disease, neurological disorders, and other conditions. The company's products are designed to help healthcare professionals make informed decisions about patient care while minimizing radiation exposure.
One of Curium Pharma's flagship products is Technetium-99m (Tc-99m), which is used in more than 80% of all nuclear medicine procedures worldwide. Tc-99m is a radioactive tracer that can be used to diagnose various medical conditions such as cancer, heart disease, bone infections or injuries etc., making it an essential tool for healthcare professionals.
In addition to Tc-99m, Curium Pharma also offers a wide range of other diagnostic radiopharmaceuticals such as Gallium-68 (Ga-68) DOTATOC/DOTATATE/DOTANOC for neuroendocrine tumors imaging; Fluorine-18 (F18) FDG for oncology imaging; Iodine -131(I131) MIBG therapy for neuroblastoma treatment; Lutetium -177(Lu177) PSMA therapy for prostate cancer treatment etc., which have been approved by regulatory authorities across the globe.
Curium pharma also provides therapeutic radiopharmaceuticals like Strontium -89(Sr89), Samarium -153(Sm153), Radium -223(Ra223), Lutetiuim –177(Lu177) PSMA therapy etc., which are used in treating various types of cancers like bone metastases from prostate cancer or breast cancer etc.
The company has invested heavily in research & development activities aimed at discovering new ways to diagnose and treat diseases using nuclear medicine technology. This investment has resulted in several breakthrough innovations such as GalliaPharm® Ga68 Generator System – A novel generator system that produces high-quality Ga68 radioisotope on-site at hospitals or clinics without requiring any cyclotron facility; PyL™(18F)-PSPC PET Imaging Agent – A novel PET imaging agent developed specifically for prostate-specific membrane antigen (PSMA)-positive lesions detection etc..
Curium pharma also offers comprehensive support services including technical support & training programs aimed at helping healthcare professionals optimize their use of radiopharmaceuticals while ensuring safety standards are met during handling & administration processes.
In conclusion, Curium pharma stands out among its competitors due to its commitment towards innovation & excellence while maintaining strict adherence towards safety standards during production & distribution processes. With its extensive product portfolio backed up by strong R&D capabilities coupled with excellent customer service offerings makes it one of the most preferred partners among healthcare providers globally who seek reliable solutions for diagnosing & treating complex medical conditions using nuclear medicine technology.